Oppenheimer analyst Jay Olson maintained a Buy rating on Biogen Inc (NASDAQ:BIIB) on Thursday, setting a price target of $325, which is approximately 15.20% above the present share price of $282.12.
Olson expects Biogen Inc to post earnings per share (EPS) of $8.10 for the second quarter of 2020.
The current consensus among 21 TipRanks analysts is for a Hold rating of shares in Biogen, with an average price target of $317.24.
The analysts price targets range from a high of $392 to a low of $240.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $3.53 billion and a net profit of $1.89 billion. The company's market cap is $45.93 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.0% and a 38.95% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.